Alexion Pharmaceuticals, Inc. (ALXN) News
Filter ALXN News Items
ALXN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
ALXN News Highlights
- 500 - Internal server error
- Over the past 24 days, the trend for ALXN's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
- The most mentioned tickers in articles about ALXN are MRNA, AZN and MG.
Latest ALXN News From Around the Web
Below are the latest news stories about Alexion Pharmaceuticals Inc that investors may wish to consider to help them evaluate ALXN as an investment opportunity.
AstraZeneca's Acquisition of Alexion Is Nearly a Done Deal, But Is It a Good Deal?AstraZeneca (NASDAQ: AZN) hopes to soon close its planned acquisition of Alexion Pharmaceuticals (NASDAQ: ALXN). In this Motley Fool Live video recorded on July 7, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not the Alexion acquisition is a good deal for AstraZeneca. Keith Speights: AstraZeneca has experienced multiple problems with the launch of its COVID-19 vaccine and we're not going to get into all of those problems but there's more news non-COVID related for AstraZeneca now. |
With the Alexion Acquisition Set to Close This Quarter, Is AstraZeneca a Buy?With UK approval, the $39 billion deal for rare disorders biotech company Alexion Pharmaceuticals is set to close on July 21. |
MRNA Stock: 10 Things to Know About Moderna as It Gets Ready to Join the S&P 500Moderna (MRNA) stock is on the rise Friday as the company prepares to join the S&P 500 next week replacing Alexion Pharmaceuticals (ALXN). |
What Did the Stock Market Do Today? 3 Big Stories to Catch Up On.What did the stock market do today? |
When Will Moderna Be Added to the S&P 500?Moderna is joining the S&P 500 on July 21, replacing Alexion Pharmaceuticals. |
MRNA Surges to Record High on Plans to Join S&P 500Moderna stock is set to join the benchmark on July 21, replacing Alexion Pharmaceuticals |
Alexion''s Ultomiris Shows Compelling, Durable Efficacy In Rare Muscle Weakness DisorderAlexion Pharmaceuticals Inc (NASDAQ: ALXN ) announced topline results from a Phase 3 study evaluating Ultomiris (ravulizumab-cwvz) in adults with generalized myasthenia gravis (gMG). The study met its primary endpoint, with a statistically significant change in MG-ADL score from baseline through Week 26 for Ultomiris compared to placebo (-3.1 versus -1.4). Myasthenia Gravis-Activities of Daily Living Profile (MG-ADL) Full story available on Benzinga.com |
Why Moderna Shares Are Rallying TodayShares of COVID-19 vaccine company Moderna, Inc. (NASDAQ: MRNA ), which ended Thursday''s session with a market cap of $104.3 billion by virtue of a 5.28% rally, are seeing follow-through buying interest Friday. Standard & Poor''s announced late Thursday Moderna will join the S&P 500 Index, effective before the market opens Wednesday, July 21. Moderna will replace Alexion Pharmaceuticals, Inc. (NASDAQ: Full story available on Benzinga.com |
Moderna Stock, Soon To Join S&P 500, Rockets To Another Record HighThe post Moderna Stock, Soon To Join S&P 500, Rockets To Another Record High appeared on BitcoinEthereumNews.com . Moderna stock rocketed to another record high on Friday on news it will join the S&P 500 on Wednesday, replacing soon-to-be-acquired Alexion Pharmaceuticals (ALXN). X The swap will occur when |
Alexion (ALXN) Reports Positive Data on Ultomiris From gMG StudyAlexion (ALXN) announces that the phase III study of Ultomiris for the indication of gMG met its primary goal. |